Ruxolitinib Cream for Facial Eczema: Why the 77-Patient Trial Needs Its Primary Result
Image: AI-created illustration of a fictional adult with dermatitis-like facial dryness. It is not a participant photograph, a diagnostic reference or a result from Dr. Arsy #003.
A prescription eczema cream can have an established overall evidence base while a smaller face-specific study still leaves uncertainty. Ruxolitinib’s facial and neck trial is a good example: the numerical difference favored the active cream, but the reported primary comparison did not reach conventional statistical significance.
This was a separate facial and neck study
The 2025 primary trial abstract describes a decentralized, randomized, double-blind phase 2 study. Eligibility was ages 12–70, with mild or moderate disease on the investigator scale, no more than 20% affected total body surface area, and at least 0.5% involving face or neck. The 77 randomized participants actually ranged from 17 to 66 years; their median age was 38. About 44.2% were Black.
Participants were assigned 2:1 to ruxolitinib cream 1.5% or vehicle, twice daily for four weeks. Everyone then had access to as-needed ruxolitinib for another four weeks. The second period therefore was not a continuation of the same vehicle-controlled comparison. Eligibility, actual enrolled ages and the current product label describe three different things.
The primary endpoint used photographs and a regional score
A blinded central reader assessed photographs to determine whether head-and-neck EASI improved by at least 75% at week four. This endpoint was regional EASI-75. It was not complete facial clearance or an all-body score, and the mean starting head-and-neck EASI was 1.2.
| Week-four primary endpoint | Ruxolitinib cream | Vehicle |
|---|---|---|
| Head-and-neck EASI-75 | 37.0% | 17.4% |
| Reported between-group test | p=0.091 | |
The numerical difference is 19.6 percentage points. A p value of 0.091 does not meet a conventional two-sided 0.05 threshold. The result should not be promoted as a statistically significant primary-endpoint success. Conversely, a small study with that result does not prove the cream has no effect on facial eczema. It leaves uncertainty about the specific comparison.
The abstract reports improvements in other measures, including investigator treatment success and patient-reported eczema burden and itch. Those findings provide context; they do not replace the primary test. We use the accessible primary abstract here and do not invent confidence intervals or a full multiplicity analysis that it does not provide.
Infrequent local reactions cannot answer every safety question
Application-site reactions were reported in one ruxolitinib-treated participant, 1.9%, and two vehicle-treated participants, 8.7%. Three total events are too few to establish that the medicine protects against irritation. Nor can a short 77-person trial rule out uncommon systemic events or prove long-term safety for every facial site or age group.
The current U.S. Opzelura label includes specified patients aged two or older with mild-to-moderate atopic dermatitis for short-term and noncontinuous chronic use when other topical prescriptions are inadequate or inadvisable. It limits affected-area treatment, includes age-specific quantity limits, and says the product is not for ophthalmic use. The facial study does not itself establish evidence in two-year-olds or authorize putting cream into the eye.
The boxed warning addresses serious infections, mortality, malignancy, major cardiovascular events and thrombosis associated with JAK-inhibitor treatment. A prescriber should assess individual risk and the full label; the small facial study cannot calculate or dismiss those risks. Combining it with therapeutic biologics, other JAK inhibitors or potent immunosuppressants is not recommended in the label.
Use the right evidence for the right decision
For the larger overall eczema studies, see our general ruxolitinib trial and label guide. A different direct facial-treatment trial illustrates why percentages from separate studies cannot rank all prescription creams. Populations, endpoints, durations and comparators differ.
Ask your clinician which face and neck areas need treatment, what response to follow and when reassessment is due. Our eyelid guidance and discussion of stinging products help frame practical concerns without choosing a prescription for you.
Dr. Arsy Moisturizer #003, 4 oz offers cosmetic hydration, moisture-barrier support and ordinary dry-skin comfort. It contains neither this study medicine nor its clinical evidence, and it does not treat eczema. Discuss a suitable moisturizer as a separate part of care.
Educational information; primary abstract and current label checked November 9, 2026.